Vyxeos (Daunorubicin/Cytarabine Lipos) Patent Expiration, LOE Window & CMS Spending

Vyxeos (Daunorubicin/Cytarabine Lipos) by Jazz Pharmaceuticals: FDA Orange Book LOE 2033-04-15, 0 AB generics, $878K 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJazz Pharmaceuticals
FDA Application & PathwayN209401 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-04-15
Orange Book Patents (*PED Extensions)15 patents (7 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$878K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$878K
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 21.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.